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Identity 
HGNC (Hugo): MAL  
Location: 2q11.1 
Local order: Centromere - TEKT4 - RPS24P6 - MAL 
- MRPS5 - ZNF514 - ZNF2 - SLC2AXP1 - PROM2 - 
Telomere. 
Note: MAL gene is the member of MAL family and 
takes part in intracellular transportation of certain 
proteins in apical direction and myelin formation. 
There is a consensus sequence shared by all family 
members, and by biochemical features (Magyar et al., 
1997; Perez et al., 1997). 
MAL has context dependent roles as both a tumor 
suppressor and an oncogene in different cancers. 
DNA/RNA 
Description 
Genomic DNA of MAL gene is located on 
chromosome 2q11.1 spans 21 kb and includes 4 exons 
interrupted by three introns. 
The promoter lacks a consensus TATA box in the 
vicinity of transcription start side and there is no 




Amplification of cDNA from different T-cell samples by PCR revealed that there are four different splicing variants of mRNA named as 
MAL-a (462 bp), MAL-b (333 bp), MAL-c (294 bp), and MAL-d (168 bp). These variants defined according to involvement of exon2 and/or 
exon3, while MAL-a includes all 4 exons. As the three introns were located between complete codons, the reading frame was maintained 
in all the transcripts. (Figure adapted from Atlas of Genetics and Cytogenetics in Oncology and Haematology). 
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There are two separated promoter CpG islands at a 
totally 1500 bp length of region extending into thefirst 
intron and contains up to 116 CpG dinucleotides. CpG 
island is divided into two regions and usually 
methylation status of these regions are evaluated 
separately by specifically designed primer sets. 
MAL promoter at 110 bp upstream of the 
transcriptional start site contains also several SP1 
binding sites, which may be regulated by 
transcriptional activator SP1 (Tugores et al., 1997). 
Transcription 
MAL coding sequence: bases 60-518, accession 
NM_002371.2. 
The mRNA is 1051 bp and open reading frame is 460 
bp in length. Translation begins from a start codon in 
exon 1, ends at a stop codon in exon 4, and results in a 
153 amino acid protein product. mRNA orientation is 
forward and transcription occurs on plus strand. The 
first exon encodes the 5' untranslated region and the 
first 31 amino acids. The second and the third exons 
encode 56 and 42 amino acids, respectively. Fourth 
exon encodes the 24 amino acids at COOH-terminal 
and the 3' untranslated region. The intron boundaries 
follow the AG/GT rule of acceptor/donor splice signal 
sequences and splicing between exons occurs between 
the last nucleotide of a codon and the first one of the 
next codon (Rancano et al., 1994b). 
Pseudogene 
There is no identified pseudogene. 
Protein 
Description 
MAL belongs to the MAL family of proteolipids 
including BENE, MAL2 and Plasmolipin. In mouse, 
the conserved motif of (Q/Y-G-W-V-M-F/Y-V), which 
is located at the junction of the first extracellular oop 
and the second membrane-associated domain serves as 
a fingerprint for the MAL family, although overall 
amino acid sequence identities between mouse MAL 
and the related proteins are between 29-37% (Magyar 
et al., 1997). This motif is also shared in human MAL 
family. 
Molecular mass of the MAL protein is 16700 Da and 
assigned into proteolipid group based on the solubility 
feature in lipophilic solvents. MAL is a non-
glycosylated integral membrane protein including four 
transmembrane domains as hydrophobic segments. 
Each of four exons encodes a hydrophobic membrane-
associated segment and its adjacent hydrophilic 
sequence in the protein structure (Rancano et al., 
1994a). A model is proposed about orientation of MAL 
protein in the membrane (Alonso et al., 1987). 
Another feature of MAL is its transmembrane helices 
constituting the MARVEL (MAL and related proteins 
for vesicle trafficking and membrane link) domain.  
This domain is also found approximately in 20 open 
reading frames of human genome (Sanchez-Pulido et 
al., 2002). Furthermore, the domain is also found in the 
tight-junction-associated proteins including occluding, 
tricellulin, marvelD3 and in the synaptic-membrane-
localized synaptophysin and synaptogyrin. Thus, a 
common characteristic of proteins containing the 
MARVEL domain is localization to specialized 
domains within surface membranes (Magal et al., 
2009). 
Expression 
Alonso and Weissman originally identified MAL 
expression in intermediate and late stages of T-
lymphocyte differentiation (Alonso and Weissman, 
1987). Furthermore, expression of MAL mRNA is also 
found to be related with differentiation in urothelial 
cells, neuronal cells (Liebert et al., 1997; Wakeman et 
al., 1997) and esophageal epithelium (Mimori et al.,
2007). Accordingly, expression is prominent in upper 
layers, while it is weak or absent in basal layers of 
esophageal epithelium (Marazuela et al., 2003). These 
results implied a strong relation between differentiation 
status and MAL expression. 
Although four transcripts identified, MAL-a variant 
containing the all four exons is found to be the most 
abundantly expressed in several tissues including 
peripheral blood lymphocytes and HNSCC tissues 
(Rancano et al., 1994b; Beder et al., 2009). 
Maruzela et al. defined a detailed expression statu for 
MAL protein by immunostaining in a wide range of 
human tissues and expression is found to be mainly 
localized in epithelial cells, myelinating cells and T-
lymphocytes (Marazuela et al., 2003). Detailed results 
according to this study: 
A- MAL negative cells and tissues:  
- Fibroblasts, endothelial cells, B lymphocytes, skeletal 
and smooth muscle, skin (keratinized squamous 
epithelium and subcutaneous fibro-adipose tissue). 
B- MAL positive cells and tissues: 
- Gastrointestinal tract: Epithelium in esophagus, 
stomach, ileum, colon, liver, and pancreas. 
- Genitourinary tract: Multiple sites of tract including 
transitional epithelium of the urothelium. 
- Respiratory tract: Ciliated columnar epithelium of 
bronchi and bronchioles, and type 2 pneumocytes of 
alveolae. 
- Hematopoietic system: Expression is restricted to 
regions rich in T-cells including cortex of thymus and 
paracortical lymphocytes of lymph node and tonsil. 
- Endocrine system: Thyroid follicular cells, medulla of 
adrenal gland. 
- Nervous system: Axons of peripheral nerves and 
myelinating Schwann cells in peripheral nervous 
system, oligodendrocytes of white and gray matter in 
central nervous system. 
- Exocrine glands: breast epithelium (Horne et al.,
2009). 
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Localisation 
The MAL proteolipid is an integral membrane protein 
and generally embedded in the plasma membrane of 
epithelial cells (Magal et al., 2009). Expression is 
generally more pronounced in supranuclear - apical 
membrane domain for most of the polarized epithelia 
including gastrointestinal mucosa and thyroid follicu ar 
cells (Marazuela et al., 2003) according with its role in 
polarized sorting. 
The protein has been mainly identified as an internal 
component of glycolipid-enriched membrane (GEM) 
domains in T-lymphocytes (Millan et al., 1997), in 
polarized epithelial MDCK cells (Zacchetti et al., 1995) 
and in myelin-forming cells (Kim et al., 1995). As 
intracellular placement, the protein is localized to 
endoplasmic reticulum of T-lymphocytes (Rancano et 
al., 1994b). 
Function 
Plasma membrane (PM) of epithelial cells divided into 
apical membrane domain involved in exchange with 
the organ lumen, and the basolateral domain 
maintaining contact with neighboring cells and the 
underlying extracellular matrix. Localizing numerous 
PM proteins to apical and basolateral domains by direct 
or indirect pathways result in cell polarization. I the 
direct pathway, proteins delivered directly from the 
trans-golgi network (TGN) to the apical PM by raft-
dependent or non-raft carriers. Rafts are clustering of 
glycospingolipids, sphingomyelin and cholesterol into 
membrane microdomains and therefore also named as 
GEM (glycosphingolipid- and cholestrol-enriched 
membrane) domains. These detergent insoluble 
membranes defined by resistancy to cold extraction 
with Triton X-100. Several proteins participate in 
structure of rafts. 
MAL is an integral membrane component of raft 
domains and recycles between the Golgi complex and 
the apical membrane in MDCK cells (Puertollano et al., 
1999a). Although, exact mechanism of MAL function 
in raft-dependent apical sorting is unknown, MAL 
family proteolipids are implicated to be potent 
regulator of apical transport by involving in the 
assembly and targeting of apical transport platforms 
and in the formation and stabilization of raft domains. 
Consensus sorting motifs in the C-terminus function in 
regulation of raft transport (Puertollano et al., 1997). 
In apical sorting, PM proteins are clustered into ei her 
glycolipid raft domains or non-raft carriers. MAL and 
MAL2 together with FAPP2 take part in constitutive 
apical transport of Influenza hemagglutinin (HA) 
(Puertollano et al., 1999b) and GPI-anchored proteins 
(decay-accelerating F factor, folate receptor, GFP-GPI, 
5'-nucleotidase, CEA) by lipid-raft-associated 
mechanism (Weisz et al., 2009).  
Based on apical sorting of many proteins, MAL is 
implied to function in establishment of cell polarity, 
however, MAL knockout mice did not display a clear 
defect in neuronal and epithelial cell polarity (Harada, 
2010). 
Related with the location of MAL in membrane 
microdomains another role is also suggested in cell 
signaling (Alonso et al., 2001), although there is yet no 
clear evidence concerning this function. 
Homology 
MAL protein is shown to be widely conserved (94-
97%) across species by sequence alignment. In MAL 
family of human, MAL displays 39% and 36% amino 
acid sequence identity with BENE and MAL2, 




Direct sequencing of the entire coding region revealed 
no somatic mutations in 20 cases of cervical cancers 
(Hatta et al., 2004) and in 24 head and neck cancer cell 
line series (Beder et al., 2009). 
Currently, there is no further data in HGMD database. 
Implicated in 
Various cancers 
Diagnostic biomarker in cancer: Recent reports 
revealed that epigenetic silencing of MAL by 
hypermethylation may be a common event involved 
during initiation and progression of epithelial caners. 
Based on specifically high hypermethylation of MAL 
promoter in various carcinomas including breast, 
cervix, colon and gastric cancers compared to normal 
epithelium, promoter methylation of the gene is 
suggested to be diagnostic marker for early detection of 
tumorigenesis (Buffart et al., 2008; Lind et al., 2008; 
Horne et al., 2009; Overmeer et al., 2009). 
Tumor-metastasis suppressive vs oncogenic role: 
Current functions attributed to MAL gene does not 
reveal a clear mechanism for MAL in oncogenesis. The
gene is suggested to have tumor suppressive role in 
some malignancies, while oncogenic role in others 
according with expression level in tumors and normal 
tissues. 
In cervical carcinoma cell lines, MAL overexpression 
by transfection reduces proliferation rate and 
suppressed migration and anchorage-dependent growth. 
Furthermore, Fas-induced apoptosis is found to be 
related with reduced migration and tumorigenicity by 
ectopic expression of MAL in esophageal carcinoma 
(Mimori et al., 2003). 
Ovarian cancer 
Note 
MAL mRNA is found to be the most differentially 
expressed gene between short and long-term survival 
groups by microarray study, and higher expression 
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MAL expression is severely down-regulated in 
esophageal carcinomas compared to normal epithelium 
(Mimori et al., 2003) and up-regulation of MAL 
expression induces differentiation in esophageal 
carcinoma cells (Mimori et al., 2007). 
Cervical carcinoma 
Note 
MAL mRNA is found to be the most significantly 
down-regulated gene both in squamous cell carcinoma 
(SCC) and adenocarcinoma of cervix (Wilting et al.,
2008). Ectopic expression of MAL in SiHa cells 
suppressed proliferation, migration, and anchorage-
independent growth. Promoter methylation is also 
remarkably high in cervical malignancies and 
accordingly showed significant correlation with 
decreased expression. Interestingly, promoter 
methylation is also shown to be predictive for high-
grade lesions of cervix i.e. severity of cervical disease 
(Overmeer et al., 2009). 
Colon carcinoma 
Note 
Genome wide microarray analysis revealed MAL to be 
frequently hypermethylated in colon carcinoma cell 
lines correlating with down-regulation of mRNA 
expression (Mori et al., 2006). Another study 
confirmed these results in carcinoma tissues and 
defined promoter hypermethylation as 71% (45/63) and 
80% (49/61) in colon adenomas and carcinomas, 
respectively, while it is rare in normal mucosa. 
Furthermore, protein expression were also absent in 
majority (198/231) colorectal carcinoma tissues in 
immunostaining (Lind et al., 2008). Based on these 
results, MAL methylation is suggested as a diagnostic 
marker for early colon carcinogenesis. 
Gastric cancer 
Note 
Promoter hypermethylation located at the transcription 
start region is correlated with down-regulation of 
mRNA expression. Furthermore, methylation of this 
region is also significant related with a better suvival 
(Buffart et al., 2008). 
Breast carcinoma 
Note 
Tumor specific hypermethylation of the MAL promoter 
is found in 100% (6/6) of the breast cancer cell lines 
and 69% (25/36) of primary tumors. Ectopic expression 
of MAL in breast carcinoma cell lines reduced motility, 
while no effect was observed on cell cycle or growth. 
Absence of MAL protein expression was highly 
associated with poor disease-free survival in patients 
not received adjuvant chemotherapy (Horne et al., 
2009). 
Head and neck squamous cell 
carcinoma (HNSCC) 
Note 
In a review of DNA microarray analysis related with 
genetic expression profiles of HNSCC, MAL is found 
to be down-regulated in 10 out of the 26 studies (Choi 
et al., 2005). Interestingly, MAL expression is down-
regulated in metastatic tumors of HNSCC including 
both cell lines derived from lymph node metastasis 
(65%) and metastatic tumor tissues (43%) compared to 
primary tumor counterparts. Furthermore, remarkable 
LOH (loss of heterozygosity) frequency (30%) is 
observed in primary tumor samples and metastatic 
tumors itself (Beder et al., 2009). These results suggest 




Like ovarian cancers, MAL overexpression is identified 
to be indicator for poor prognosis and disease outcome 
in patients with T cell lymphoma and Hodgkin 
lymphoma (Tracey et al., 2002; Hsi et al., 2006). 
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